RxDoctor Payments DataLook up a doctor →

Kaitlyn Pierce

Adult Health · Pell City, ALNPI 1790243582

Payments from drug & device makers

$7,864in general payments, 2019–2025

Across 521 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$868
  • Amgen$560
  • Lilly USA, LLC$446
  • GSK$370
  • Bayer$363
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$1752%
  • Food & beverage$7,66397%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,864 in reported general payments places this provider in the 90th percentile of 308 adult health providers in Alabama.

See all adult health providers in Alabama

Medicare billing

Part B allowed, 2024
$24,724
Medicare patients
79
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide107$115,412
OzempicSemaglutide77$91,767
JardianceEmpagliflozin54$59,908
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$50,954
TrulicityDulaglutide26$30,907
XareltoRivaroxaban17$25,111
EliquisApixaban32$22,811
MyrbetriqMirabegron33$17,868
LinzessLinaclotide22$17,185
LivaloPitavastatin Calcium20$13,894
RybelsusSemaglutide12$12,058
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,901
FarxigaDapagliflozin Propanediol18$10,440
Repatha SureclickEvolocumab15$9,313
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$7,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$446$146,319133 claims
Novo NordiskOzempic, Rybelsus$1,277$103,82589 claims
GSKTrelegy Ellipta, Anoro Ellipta$370$62,85589 claims
Boehringer IngelheimJardiance$111$59,90854 claims
Johnson & JohnsonXarelto$119$25,11117 claims
PfizerEliquis$324$22,81132 claims
AbbVieLinzess$868$17,18522 claims
Kowa Pharmaceuticals America, Inc.Livalo$126$13,89420 claims
AstraZenecaFarxiga, Nexium$357$13,40029 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$115$5,98313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 adult health providers in Alabama.

Other adult health in Pell City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →